Tag: budesonide market value

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Budesonide Industry By The Forecast Year 2029?

The budesonide market has experienced substantial growth in recent years. It is anticipated to expand from $9.72 billion in 2024 to $10.26 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.6%. This historical growth can be linked to several factors including the rising prevalence of respiratory diseases, greater awareness of inhaled corticosteroids, the introduction of budesonide-based combination therapies, the expansion of healthcare access and infrastructure, and the adoption of budesonide for off-label applications in inflammatory bowel diseases.

The budesonide market is poised for significant expansion in the coming years. It is projected to reach $12.95 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.0%. This growth during the forecast period is attributed to several factors, including the increasing demand for effective treatments, the development of novel drug delivery systems, the expanding use of budesonide, a rising geriatric population susceptible to asthma, and the proliferation of generic budesonide products. Key trends anticipated in this period encompass the adoption of biologics and biosimilars, ongoing advancements in drug delivery systems, regulatory approvals for new formulations, and broader technological development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Budesonide Industry?

The rising occurrence of respiratory conditions is anticipated to propel the growth of the budesonide market moving forward. Respiratory diseases are defined as medical conditions that affect the organs and tissues responsible for regulating gas exchange in air-breathing animals. This increase in the prevalence of respiratory diseases stems from escalating air pollution, particularly exposure to particulate matter and allergens, which significantly impacts the prevalence of asthma and chronic obstructive lung disease. Budesonide is utilized in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation, improve airflow, and prevent symptoms like wheezing and shortness of breath. For instance, in May 2024, according to the National Center for Health Statistics (NCHS), a US-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes in the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. Therefore, the growing prevalence of respiratory diseases will drive the expansion of the budesonide market.

How Is The Budesonide Market Segmented?

The budesonide market covered in this report is segmented –

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications

Subsegments:

1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)

2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers

3) By Injectable Suspension: Pre-filled Syringes, Vials

4) By Tablets And Capsules: Oral Tablets, Oral Capsules

How Are Trends Influencing The Budesonide Market?

Key companies within the budesonide market are directing their efforts towards breakthroughs in respiratory treatment, including oral therapy, aiming to boost patient comfort, ensure better treatment adherence, and widen the range of therapeutic choices for managing asthma and other respiratory issues. Oral therapy budesonide is a version of budesonide administered by mouth, primarily employed in treating inflammatory conditions. As an illustration, in February 2024, Takeda Pharmaceuticals, a pharmaceutical firm from Japan, declared that the Food and Drug Administration (FDA), a US federal body, had given its approval to EOHILIA, an oral suspension of budesonide, making it the first and sole FDA-cleared oral medicine for individuals aged 11 and above afflicted with eosinophilic esophagitis (EoE). Additionally, the FDA authorized EOHILIA 2 mg twice daily, basing its decision on efficacy and safety information gathered from two 12-week multicenter, randomized, double-blind, parallel-group, placebo-controlled studies conducted on participants aged 11 to 56 with EoE.

Which Key Players Are Driving Competition In The Budesonide Market?

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report

Which Geographies Are Emerging As Strong Markets For The Budesonide Industry?

North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Budesonide Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp

Browse Through More Reports Similar to the Global Budesonide Market 2025, By The Business Research Company

Corticosteroid Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/corticosteroid-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Non Steroidal Anti Inflammatory Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Budesonide Market Expected To Grow In Terms Of Size?

The budesonide market has witnessed significant expansion in the past few years. From $9.72 billion in 2024, it is projected to reach $10.26 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 5.6%. Factors that contributed to this increase throughout the historic period encompass the escalating instances of respiratory ailments, heightened awareness regarding inhaled corticosteroids, the launch of budesonide-based combined therapies, enhanced access to healthcare and improvement in healthcare infrastructures, as well as the approval of budesonide for off-label use to treat inflammatory bowel diseases.

In the upcoming years, the budesonide market is projected to experience robust growth, expanding to “$12.95 billion in 2029 with a compound annual growth rate (CAGR) of 6.0%. The anticipated increase in the forecast period is due to rising demand for effective therapies, the introduction of innovative drug delivery systems, the growing usage of budesonide, an increase in the elderly population susceptible to asthma, and the proliferation of generic budesonide products. Key trends expected during the forecast period include the implementation of biologics and biosimilars, advancements in drug delivery methods, regulatory approvals for new formulations, breakthroughs in drug delivery system development, and technological progression.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Budesonide Market?

The growth of the budesonide market is expected to be accelerated by a surge in the incidence of respiratory conditions. Such conditions include diseases impacting the organs and tissues in air-breathing animals that are involved in gas exchange. The rising prevalence of these conditions can be attributed to increased air pollution, including exposure to particulates and allergens, which notably influence the occurrence of asthma and chronic obstructive lung disease. Budesonide is employed as treatment for these conditions, including asthma and chronic obstructive pulmonary disease (COPD), as it reduces inflammation, improves airflow, and prevents symptoms like wheezing and breathlessness. For instance, the National Center for Health Statistics (NCHS), a US-based health statistics agency, reported in May 2024 that the current asthma prevalence among adults over 18 in the United States climbed from 8.4% in 2021 to 8.7% in 2022. Moreover, the number of asthma episodes that occurred among adults of the same age group in the past 12 months increased from 3.3% in 2021 to 3.7% in 2022. Consequently, the rising incidence of respiratory conditions is expected to prompt growth within the budesonide market.

Which Segment Accounts For The Largest Share In The Budesonide Market?

The budesonide market covered in this report is segmented –

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications

Subsegments:

1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)

2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers

3) By Injectable Suspension: Pre-filled Syringes, Vials

4) By Tablets And Capsules: Oral Tablets, Oral Capsules

Which Long-Term Trends Will Play A Crucial Role In The Budesonide Market?

Leading firms in the budesonide market are prioritizing innovations in respiratory care, like oral treatments, to not only enhance patient comfort but also expand therapy choices for dealing with asthma and other respiratory diseases. Oral budesonide, which is ingested, is mainly used for inflammatory conditions. For example, in February 2024, Japan’s Takeda Pharmaceuticals revealed that EOHILIA, an oral suspension of budesonide, has been approved as the first and sole oral drug for eosinophilic esophagitis (EoE) in patients aged 11 and older by the Food and Drug Administration (FDA), a federal agency in the US. Moreover, based on efficacy and safety data from two multicenter, randomized, double-blind, parallel-group, placebo-controlled 12-week studies in people aged 11 to 56 with EoE, the FDA also greenlighted EOHILIA 2 mg to be used twice daily.

Which Organizations Are At The Forefront Of The Budesonide Market?

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report

Which Region Is Forecasted To Lead The Budesonide Market In The Coming Years?

North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Does the Forecast Indicate for the Cell Regeneration Medicine Market From 2025 to 2029?#_x000D_

In recent years, the budesonide market has demonstrated robust growth. The market, which was worth $9.72 billion in 2024, is projected to escalate to $10.26 billion in 2025, displaying a compound annual growth rate (CAGR) of 5.6%. Various factors have propelled this growth during the historic period, which include the proliferating incidence of respiratory diseases, enhanced consciousness regarding inhaled corticosteroids and the roll-out of combination therapies involving budesonide. Additionally, the growth of healthcare facilities and increased access to them and the off-label utilization of budesonide in treating inflammatory bowel diseases have also contributed to this increase._x000D_

_x000D_

In the upcoming years, the budesonide market is anticipated to witness robust expansion, proliferating to “$12.95 billion by 2029 at a CAGR of 6.0%. The expansion during the forecast period is owing to factors such as the increased need for potent treatments, the evolution of innovative drug delivery methods, heightened usage of budesonide, a growing elderly population susceptible to asthma, and the proliferation of generic budesonide products. Major forecasts for the period include the embracement of biologics and biosimilars, improvement in drug delivery systems, regulatory endorsements for new formulations, the evolution of innovative drug delivery platforms, and technological progress._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp_x000D_

_x000D_

#What Elements Are Contributing To Growth In The Cell Regeneration Medicine Market?#_x000D_

The cell regeneration medicine market is forecasted to grow, spurred by the increasing acceptance of organ transplantation. This medical procedure involves transferring an organ from one body to another, substituting a damaged or lost organ. Its popularity has surged due to the extended lifespan it offers and the sidestepping of medical processes like dialysis. Cell regeneration medicine significantly upgrades organ transplantation by concentrating on the repair and regeneration of impaired tissues or organs. In January 2023, the United Network for Organ Sharing, a scientific and educational association based in the US, reported that approximately 42,887 organ transplants performed in the US in 2022, marking a 3.7% rise from 2021. Consequently, the escalating acceptance of organ transplants will stimulate the cell regeneration medicine market._x000D_

_x000D_

_x000D_

The budesonide market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules_x000D_

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI) _x000D_

2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers _x000D_

3) By Injectable Suspension: Pre-filled Syringes, Vials _x000D_

4) By Tablets And Capsules: Oral Tablets, Oral Capsules_x000D_

_x000D_

#What Are The Leading Trends And Opportunities In The Cell Regeneration Medicine Sector?#_x000D_

Leading firms in the budesonide market are prioritizing innovations in respiratory treatments like oral therapy, aiming to increase patient comfort, enhance adherence to therapy, and broaden the range of therapeutic solutions for managing asthma and other respiratory problems. The oral budesonide therapy is a formulation consumed orally, mainly for treating inflammatory conditions. In February 2024, for example, Takeda Pharmaceuticals, a pharmaceutical company from Japan, revealed that the US’ Food and Drug Administration (FDA) had given approval to EOHILIA, a budesonide oral suspension, making it the first and sole FDA-approved oral drug for patients aged 11 and above with eosinophilic esophagitis (EoE). Also, the FDA approved the twice-daily use of EOHILIA 2 mg, based on efficacy and safety data gathered from two 12-week multicenter, randomized, double-blind, parallel group, placebo-controlled studies involving individuals aged 11 to 56 with EoE._x000D_

_x000D_

#Who Are The Key Contributors To Growth In The Cell Regeneration Medicine Market?#_x000D_

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd. _x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report_x000D_

_x000D_

#Which Region Is Projected To Lead The Cell Regeneration Medicine Market By 2025?#_x000D_

North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Current and Projected Market Size of the Budesonide Market Through 2034?#_x000D_

Over the past few years, the budesonide market has experienced robust growth. It is projected to expand from $9.72 billion in 2024 to $10.26 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.6%. The growth observed in the past can be credited to the increasing incidence of respiratory diseases, heightened awareness of inhaled corticosteroids, the development and introduction of combination therapies involving budesonide, the enhancement and spread of healthcare infrastructure, as well as the utilization of budesonide for off-label treatments of inflammatory bowel diseases._x000D_

_x000D_

The market size of budesonide is set to experience robust growth in the upcoming years, reaching a valuation of $12.95 billion by 2029, with a compound annual growth rate (CAGR) of 6.0%. The surge during the projected period can be ascribed to the increasing demand for efficient treatment methods, the advent of new drug delivery systems, the rising utilization of budesonide, a growing elderly population susceptible to asthma, and the proliferation of generic budesonide products. Notable trends in the forecast period consist of the uptake of biologics and biosimilars, enhancements in drug delivery systems, regulatory green lights for new formulations, the creation of innovative drug delivery systems, and technological progression._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp_x000D_

_x000D_

#Which Major Market Drivers Are Expected to Boost the Growth Potential of the Budesonide Market?#_x000D_

The rise in respiratory diseases is poised to fuel the expansion of the budesonide market. Respiratory conditions are medical issues that affect the structures and organs responsible for gas exchange in creatures capable of breathing air. The growth in these diseases can be attributed to increased air pollution, specifically exposure to particulate matter and allergens, which greatly influences the occurrence of asthma and chronic obstructive lung disease. Budesonide is utilized to manage respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD), reducing inflammation, enhancing airflow, and warding off symptoms such as shortness of breath and wheezing. For example, as reported by the National Center for Health Statistics (NCHS), a health statistics organization based in the United States, in May 2024, the prevalence of current asthma among adults aged 18 and up in the US rose from 8.4% in 2021 to 8.7% in 2022. Furthermore, the rate of asthma episodes in the past year for adults of the same age bracket increased from 3.3% in 2021 to 3.7% in 2022. Hence, the escalation in respiratory diseases is set to bolster the budesonide market’s development._x000D_

_x000D_

#Which Key Market Segments Comprise the Budesonide Market and Drive Its Revenue Growth?#_x000D_

The budesonide market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules_x000D_

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI) _x000D_

2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers _x000D_

3) By Injectable Suspension: Pre-filled Syringes, Vials _x000D_

4) By Tablets And Capsules: Oral Tablets, Oral Capsules_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Budesonide Market Expansion Across the Globe?#_x000D_

North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Key Market Trends in theBudesonide Market Over the Coming Years?#_x000D_

Leading enterprises in the budesonide market are prioritizing innovation in respiratory treatments. This includes oral therapy, improving convenience for patients, increasing adherence to treatment, and broadening the range of therapies available for asthma and other respiratory diseases. Budesonide oral therapy is a type of treatment taken orally, primarily aimed at managing inflammation. For example, Takeda Pharmaceuticals, a Japanese pharmaceutical company, declared in February 2024 that their budesonide oral suspension, EOHILIA, has gained approval from the US-based Food and Drug Administration (FDA) as the inaugural FDA-crusted oral drug for patients 11 years old and over with eosinophilic esophagitis (EoE). The FDA also approved EOHILIA 2 mg twice each day, backed by effectiveness and safety details from two multi-site, randomized, double-blind, parallel-group, placebo-controlled studies that lasted for 12 weeks and involved people aged 11 to 56 with EoE._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report_x000D_

_x000D_

#How Is the Budesonide Market Conceptually Defined?#_x000D_

Budesonide is a corticosteroid medication used to reduce inflammation in conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (Crohn’s disease, ulcerative colitis), and allergic rhinitis. It works by suppressing the immune response and decreasing inflammation in the airways or digestive tract._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21121_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Budesonide Market?

In recent times, there has been a significant expansion in the market size of budesonide. It is projected to rise from $9.72 billion in 2024 to $10.36 billion in 2025, marking a compound annual growth rate (CAGR) of 6.6%. This robust growth during the historical period can be traced back to factors such as the increasing incidence of respiratory ailments, heightened awareness about inhaled corticosteroids, the unveiling of combination therapies involving budesonide, the development of healthcare infrastructure and accessibility, and the approval of budesonide for unofficial use in managing inflammatory bowel diseases.

What Growth Rate Is Forecasted for the Budesonide Market by 2029?

The market for budesonide is anticipated to witness considerable expansion in the next few years, escalating to $13.25 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. The growth in this forecast period is a result of the increasing need for effective medicinal solutions, advent of innovative drug delivery mechanisms, elevated use of budesonide, growing older population susceptible to asthma, and broadening of the generic budesonide product range. Noteworthy trends during this projected period incorporate the embrace of biologics and biosimilars, progress in medicinal delivery systems, validation of fresh formulations, creation of groundbreaking drug delivery methods, and advancements in technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

Which Key Companies Are Shaping the Future of the Budesonide Market?

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

Which Factors Are Driving Demand in the Budesonide Industry?

The rising prevalence of respiratory illnesses is predicted to fuel the expansion of the budesonide market. Respiratory conditions are medical disorders that impact the organs and tissues responsible for gas exchange in animals that breathe air. This surge in respiratory conditions is connected to growing air pollution, specifically contact with particulate matter and allergens, which greatly influences the incidence of asthma and chronic obstructive lung disease. Budesonide is employed in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) to diminish inflammation, enhance airflow, and avert symptoms like wheezing and breathlessness. For example, in May 2024, the National Center for Health Statistics (NCHS), a health statistics institution in the US, reported that the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Moreover, the occurrence of asthma episodes in the preceding 12 months for adults within the same age range increased from 3.3% in 2021 to 3.7% in 2022. Consequently, the rising prevalence of respiratory diseases will stimulate the growth of the budesonide market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp

How Is the Budesonide Market Segmented by Several Divisions?

The budesonide market covered in this report is segmented –

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications

Subsegments:

1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)

2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers

3) By Injectable Suspension: Pre-filled Syringes, Vials

4) By Tablets And Capsules: Oral Tablets, Oral Capsules

What are the Emerging Market Trends Driving the Growth of the Budesonide Industry?

Significant businesses within the budesonide market are channeling their energy towards advancements in respiratory treatments, including oral therapy, with intentions to improve the convenience for the patient, enforce better adherence to treatment, and widen the selection of therapeutic options for managing asthma and other respiratory related issues. Oral budesonide therapy is an administered treatment taken orally, used predominantly to combat inflammatory conditions. As a case in point, Takeda Pharmaceuticals, a pharmaceutical business based in Japan, declared in February 2024 that the US Federal agency, the Food and Drug Administration (FDA), granted approval for EOHILIA, a budesonide oral suspension. This marked EOHILIA as the first and sole oral medication sanctioned by the FDA, aimed for patients aged 11 and older diagnosed with eosinophilic esophagitis (EoE). Following this, the FDA also sanctioned EOHILIA 2 mg to be taken twice daily, based on efficacy and safety results from a pair of multicenter, randomized, double-blind, placebo-controlled 12-week studies involving individuals aged 11 to 56 suffering from EoE.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report

Which Regions Are Driving Growth in the Budesonide Market?

North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21121

This Report Delivers Insight On:

1. How big is the budesonide market, and how is it changing globally?

2. Who are the major companies in the budesonide market, and how are they performing?

3. What are the key opportunities and risks in the budesonide market right now?

4. Which products or customer segments are growing the most in the budesonide market?

5. What factors are helping or slowing down the growth of the budesonide market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theBudesonide Market?

The increasing prevalence of respiratory diseases is also expected to drive the growth of the budesonide market. Respiratory diseases refer to medical conditions that impact the organs and tissues involved in gas exchange in air-breathing animals. This rise in respiratory diseases is primarily due to growing air pollution, particularly exposure to particulate matter and allergens, which significantly affect asthma and chronic obstructive pulmonary disease (COPD). Budesonide is used to treat asthma and COPD, reducing inflammation, enhancing airflow, and alleviating symptoms such as wheezing and shortness of breath. In May 2024, the National Center for Health Statistics (NCHS) reported that the prevalence of current asthma among U.S. adults aged 18 and older increased from 8.4% in 2021 to 8.7% in 2022. Moreover, the number of asthma episodes in the past 12 months increased from 3.3% in 2021 to 3.7% in 2022. Thus, the rising prevalence of respiratory diseases is propelling the growth of the budesonide market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

What is the Predicted Annual Growth Rate of theBudesonide Market Impact Industry Trends by 2034?

The budesonide market has shown strong growth, expected to rise from $9.72 billion in 2024 to $10.36 billion in 2025 at a CAGR of 6.6%. Growth in previous years was driven by the increasing prevalence of respiratory diseases, greater awareness of inhaled corticosteroids, the introduction of combination therapies, expansion of healthcare access, and the use of budesonide for off-label inflammatory bowel disease treatment.

The budesonide market is projected to experience solid growth, expanding to $13.25 billion by 2029 at a CAGR of 6.3%. Key factors driving this expansion include increasing demand for effective treatments, novel drug delivery systems, rising use of budesonide, an aging population prone to asthma, and the growing availability of generic budesonide products. Notable trends include the rising adoption of biologics and biosimilars, advancements in drug delivery technology, regulatory approvals for new formulations, continued innovations in drug administration, and broader technological developments in the pharmaceutical sector.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21121

Which Upcoming Market Trends and Innovations Are Set to Influence theBudesonide Market’s Path Forward?

In the budesonide market, companies are advancing oral therapy formulations to enhance patient convenience and adherence for respiratory conditions. For instance, in February 2024, Takeda Pharmaceuticals, a Japan-based company, received FDA approval for EOHILIA, an oral budesonide suspension. This is the first FDA-approved oral medication for eosinophilic esophagitis (EoE) in patients aged 11 and older, providing a convenient treatment option for managing this condition.

Who Are the Dominant Market Players Pushing the Boundaries of theBudesonide Market?

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report

What Are the Core Segments of the Budesonide Market, and How Do They Contribute to Growth?

The budesonide market covered in this report is segmented –

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications

Subsegments:

1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)

2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers

3) By Injectable Suspension: Pre-filled Syringes, Vials

4) By Tablets And Capsules: Oral Tablets, Oral Capsules

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp

What Regions Are Dominating the Budesonide Market Growth?

North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Budesonide Market 2025, By The Business Research Company:

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

Vascular Embolization Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vascular-embolization-global-market-report

Inhalation And Nasal Spray Generic Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Are the Projected Expansion Rates of the Budesonide Market for the Next Decade?

The scale of the budesonide market has seen a noticeable increase in recent years. The market, which was valued at $9.72 billion in 2024, is expected to surge to $10.36 billion in 2025, exhibiting a compound annual growth rate of 6.6%. Various factors contributed to this impressive growth, including the increasing incidence of respiratory illnesses, heightened understanding of inhaled corticosteroids, the emergence of combination treatments utilizing budesonide, the widening scope of healthcare facilities and infrastructures, and the utilization of budesonide for unapproved indications in the context of inflammatory bowel diseases.

In the coming years, a robust increase is anticipated in the budesonide market size, expanding to $13.25 billion in 2029, with a CAGR of 6.3%. This surge during the forecast period can be credited to the escalating demand for efficient therapies, the emergence of innovative drug delivery systems, the amplified use of budesonide, the aging population vulnerable to asthma, and the growth of generic budesonide products. Key trends during this time include the uptake of biologics and biosimilars, progress in drug delivery systems, getting new formulations approved by regulatory bodies, the invention of new drug delivery mechanisms, and advancements in technology.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the Budesonide Market?

The escalating prevalence of respiratory illnesses is projected to fuel the expansion of the budesonide market. These illnesses involve conditions that impact the body’s ability to exchange gases, commonly reported within animals that breathe air. This rise in respiratory diseases incidence is primarily attributed to increasing air contamination, with a particular emphasis on exposure to particulate matter and allergens. These factors significantly influence the occurrence of asthma and chronic obstructive lung disease. Budesonide serves as a remedy for respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), as it diminishes inflammation, ameliorates airflow, and deters symptoms such as wheezing and difficulty breathing. For example, per the National Center for Health Statistics (NCHS), a health statistics institution in the United States, the prevalence of present-day asthma among adults 18 and older escalated from 8.4% in 2021 to 8.7% in 2022. Moreover, the number of asthma incidents within the previous 12 months for adults within that age bracket went up from 3.3% in 2021 to 3.7% in 2022. Consequently, the surge in respiratory diseases prevalence will stimulate the growth of the budesonide market.

Get Your Free Sample of the Global Budesonide Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

Which Companies Are Redefining the Future of the Budesonide Market?

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

What Trends Are Poised to Drive the Future Success of the Budesonide Market?

Top firms active in the budesonide market are concentrating on developing advancements in respiratory care, including oral treatment methods, to enhance patient comfort, increase adherence to treatment regimes, and broaden the therapeutic choices for dealing with asthma and other respiratory diseases. Oral budesonide is a formulation of budesonide taken orally, primarily used to manage inflammation. For instance, Takeda Pharmaceuticals, based out of Japan, announced in February 2024 that the US federal agency, the Food and Drug Administration (FDA), has granted authorization for EOHILIA, an oral suspension of budesonide, making it the first and only FDA-approved oral medication for patients 11 years old and above diagnosed with eosinophilic esophagitis (EoE). In addition, the FDA has approved a 2 mg twice-daily dose of EOHILIA based on its efficacy and safety data, which comes from two multi-center, randomized, double-blind, parallel-group, placebo-controlled 12-week trials involving individuals aged 11 to 56 with EoE.

Get Instant Access to the Global Budesonide Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report

How Are Key Segments Defining the Competitive Landscape of the Budesonide Market?

The budesonide market covered in this report is segmented –

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications

Subsegments:

1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)

2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers

3) By Injectable Suspension: Pre-filled Syringes, Vials

4) By Tablets And Capsules: Oral Tablets, Oral Capsules

What Are the Leading Regions in the Budesonide Market Expansion?

North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Core Features That Define the Budesonide Market?

Budesonide is a corticosteroid medication used to reduce inflammation in conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (Crohn’s disease, ulcerative colitis), and allergic rhinitis. It works by suppressing the immune response and decreasing inflammation in the airways or digestive tract.

Browse Through More Similar Reports By The Business Research Company:

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

Vascular Embolization Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vascular-embolization-global-market-report

Inhalation And Nasal Spray Generic Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: